N4P.L
N4 Pharma Plc, a specialist pharmaceutical company, develops novel silica nanoparticle delivery system for pharmaceutical and biotechnology companies in the United Kingdom. It develops Nuvec, a non-viral adjuvant delivery system for vaccines and cancer treatments. N4 Pharma Plc was incorporated in 1979 and is based in London, the United Kingdom.
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
1988-07-01
Stock Exchange
LSE
Ticker
N4P.L
According to N4 Pharma Plc’s latest financial reports and current stock price. The company's current PE Ratio is -0.54. This represents a change of -35.60% compared to the average of -0.84 of the last 4 quarters.
The mean historical PE Ratio of N4 Pharma Plc over the last ten years is -13.80. The current -0.54 PE Ratio has changed 291.26% with respect to the historical average. Over the past ten years (40 quarters), N4P.L's PE Ratio was at its highest in in the June 2009 quarter at 25.09. The PE Ratio was at its lowest in in the June 2016 quarter at -74.69.
Average
-13.80
Median
-3.47
Minimum
-103.38
Maximum
-0.24
Discovering the peaks and valleys of N4 Pharma Plc PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 42.58%
Maximum Annual PE Ratio = -0.24
Minimum Annual Increase = -96.54%
Minimum Annual PE Ratio = -103.38
| Year | PE Ratio | Change |
|---|---|---|
| 2024 | -1.69 | 3.72% |
| 2023 | -1.63 | -51.46% |
| 2022 | -3.35 | -35.78% |
| 2021 | -5.22 | -40.16% |
| 2020 | -8.72 | 177.35% |
| 2019 | -3.14 | -55.44% |
| 2018 | -7.06 | 97.15% |
| 2017 | -3.58 | -96.54% |
| 2016 | -103.38 | 42.58% |
| 2015 | -0.24 | -56.44% |
The current PE Ratio of N4 Pharma Plc (N4P.L) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-2.22
5-year avg
-4.12
10-year avg
-13.80
N4 Pharma Plc’s PE Ratio is greater than Chill Brands Group PLC (-1.21), greater than Proteome Sciences plc (-1.82), greater than Theracryf Plc (-0.66), greater than CRISM Therapeutics Corporation (-3.14), greater than Tissue Regenix Group plc (-5.72), greater than MyHealthChecked PLC (-2.34), less than Genedrive Plc (-0.25), less than Feedback plc (-0.47), greater than Surgical Innovations Group plc (-3.28), less than Oxford BioDynamics Plc (-0.17),
| Company | PE Ratio | Market cap |
|---|---|---|
| -1.21 | N/A | |
| -1.82 | N/A | |
| -0.66 | N/A | |
| -3.14 | N/A | |
| -5.72 | N/A | |
| -2.34 | N/A | |
| -0.25 | N/A | |
| -0.47 | N/A | |
| -3.28 | N/A | |
| -0.17 | N/A |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like N4 Pharma Plc using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like N4 Pharma Plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is N4 Pharma Plc's PE Ratio?
How is the PE Ratio calculated for N4 Pharma Plc (N4P.L)?
What is the highest PE Ratio for N4 Pharma Plc (N4P.L)?
What is the 3-year average PE Ratio for N4 Pharma Plc (N4P.L)?
What is the 5-year average PE Ratio for N4 Pharma Plc (N4P.L)?
How does the current PE Ratio for N4 Pharma Plc (N4P.L) compare to its historical average?